High sensitive- C reactive protein, periodontal parameters and periodontal microbiota after scaling-root planning plus Azithromycin as treatment of Chronic Periodontitis: A Randomized Clinical Trial

  • Jorge-Enrique Soto-Franco Universidad del Valle. Cali, Colombia.
  • Heberth-Fernando Aldana Universidad del Valle. Cali, Colombia.
  • Juan-Manuel Navia Odontólogo, Especialista en Periodoncia
  • Melissa Peláez Universidad del Valle. Cali, Colombia.
  • Jorge Quisoboni Universidad del Valle. Cali, Colombia.
  • María-Alexandra O'Meara Universidad del Valle. Cali, Colombia.
  • Adolfo Contreras Universidad del Valle. Cali, Colombia.

Abstract

Objective: This single blind randomized clinical trial (RCT) determined the effect of scaling and root planning plus azithromycin (SRP+Azi) in serum C reactive protein levels and other blood biomarkers, clinical periodontal parameters and subgingival microbial composition three months after periodontal therapy.


Materials and Methods: Forty-nine chronic periodontitis patients participatedin the study and were randomly assignedsession of scaling and root planning plus oral azithromycin 500 mg daily for five days (SRP+Azi) while, 27 patients in the control group received the same single session of scaling and root planning plus placebo (SRP+Pb). A group of 25 subjects presenting periodontal health-gingivitis were included as a comparison group and in them was determined clinical periodontal parameters, blood parameters and microbiota at baseline. Periodontitis groups received a full mouth periodontal examination, blood test and microbiological cultures at baseline, and three months after therapy.


Primary outcome variable was the variation in serum high sensitive C- reactive protein (hs-CRP). Secondary outcome variables were variation of triglycerides, High density Cholesterol (HDL), low density Cholesterol (LDL), fasting glucose, pocket depth and microbial composition.


Results: Therapy with SRP+Azi do not significantly reduce the plasmatic levels of hs-CRP however, a positive trend was notice (4,33 to 2,99 mg/l). This group obtained also greater reduction of pocket depth (PD), artery index and P. gingivalis and P intermedia detection frequency when compared to the SRP placebo group (p<0.05). Other blood biochemistry parameters did not changed significantly in the test group. In contrast, the control group increased the hs- CRP levels after therapy and in some cases a increase of pocket depth was detected.


Conclusions: Combined SRP+Azi therapy in chronic periodontitis did not reduced hs- CRP serum level significantly after three months. However, this group reduced significantly their probing pocket depth, reduced P. gingivalis and P intermedia frequency and increased clinical attachment gain.


Key words: Chronic periodontitis, Creactive protein, azithromycin, randomized clinical trial.

Downloads

Download data is not yet available.

Abstract

Objective: This single blind randomized clinical trial (RCT) determined the effect of scaling and root planning plus azithromycin (SRP+Azi) in serum C reactive protein levels and other blood biomarkers, clinical periodontal parameters and subgingival microbial composition three months after periodontal therapy.


Materials and Methods: Forty-nine chronic periodontitis patients participatedin the study and were randomly assignedsession of scaling and root planning plus oral azithromycin 500 mg daily for five days (SRP+Azi) while, 27 patients in the control group received the same single session of scaling and root planning plus placebo (SRP+Pb). A group of 25 subjects presenting periodontal health-gingivitis were included as a comparison group and in them was determined clinical periodontal parameters, blood parameters and microbiota at baseline. Periodontitis groups received a full mouth periodontal examination, blood test and microbiological cultures at baseline, and three months after therapy.


Primary outcome variable was the variation in serum high sensitive C- reactive protein (hs-CRP). Secondary outcome variables were variation of triglycerides, High density Cholesterol (HDL), low density Cholesterol (LDL), fasting glucose, pocket depth and microbial composition.


Results: Therapy with SRP+Azi do not significantly reduce the plasmatic levels of hs-CRP however, a positive trend was notice (4,33 to 2,99 mg/l). This group obtained also greater reduction of pocket depth (PD), artery index and P. gingivalis and P intermedia detection frequency when compared to the SRP placebo group (p<0.05). Other blood biochemistry parameters did not changed significantly in the test group. In contrast, the control group increased the hs- CRP levels after therapy and in some cases a increase of pocket depth was detected.


Conclusions: Combined SRP+Azi therapy in chronic periodontitis did not reduced hs- CRP serum level significantly after three months. However, this group reduced significantly their probing pocket depth, reduced P. gingivalis and P intermedia frequency and increased clinical attachment gain.


Key words: Chronic periodontitis, Creactive protein, azithromycin, randomized clinical trial.

Author Biographies

Jorge-Enrique Soto-Franco, Universidad del Valle. Cali, Colombia.

Odontólogo, Especialista en Periodoncia, Profesor titular de la Escuela de Odontología

Heberth-Fernando Aldana, Universidad del Valle. Cali, Colombia.

Odontólogo, Especialista en Periodoncia

Melissa Peláez, Universidad del Valle. Cali, Colombia.

Bacterióloga, Laboratorio de Virología

Jorge Quisoboni, Universidad del Valle. Cali, Colombia.

Odontólogo, Especialista en Periodoncia

María-Alexandra O'Meara, Universidad del Valle. Cali, Colombia.

Odontólogo, Especialista en Periodoncia

Adolfo Contreras, Universidad del Valle. Cali, Colombia.

Odontólogo, Magíster en Microbiología, Doctor en Biología Craneofacial, Profesor titular de la Escuela de Odontología

References

1. Lazzini A, Lazzini S. Cardiovascular disease: an economical perspective. Curr Pharm Des 2009; 15 (10):1142-56.

2. Levi F, Chatenoud L, Bertuccio P, Lucchini F, Negri E, La Vecchia C. Mortality from cardiovascular and cerebrovascular
diseases in Europe and other areas of the world: an update. Eur J Cardiovasc Prev Rehabil. 2009; 16(3):333-50.

3. Wood D. Established and emerging cardiovascular risk factors. Am Heart J 2001; 141(2 Suppl):S49-57.

4. Mukamal KJ, Kronmal RA, Tracy RP, Cushman M, Siscovick DS. Traditional and novel risk factors in older adults: cardiovascular risk assessment late in life. Am J Geriatr Cardiol. 2004; 13(2):69-80.

5. H a n s s o n G K . I n f l amma t i o n , atherosclerosis, and coronary artery disease. N Engl J Med. 2005; 352(16): 1685-95.

6. Papapanou PN. Periodontal diseases: epidemiology. Ann Periodontol. 1996; 1(1):1-36.

7. Kassebaum NJ, Bernabé E, et al. Global burden of severe periodontitis in 1990- 2010: a systematic review and metaregression
J Dent Res. 2014; 93(11): 1045-53.

8. Eke PI, Dye BA, Wei L, Thornton-Evans GO, Genco RJ. Prevalence of periodontitis in adults in the United States: 2009 and
2010. J Dent Res 2012; 91(10): 914-920.

9. Ministerio de Salud. República de Colombia. IV Estudio Nacional de Salud Bucal ENSAB-IV 2013-2014. Situación en Salud Bucal, 2015: 78.

10. Ebersole JL, Machen RL, Steffen MJ, Willmann DE. Systemic acutephase reactants, C-reactive protein and haptoglobin, in adult periodontitis. Clin Exp Immunol. 1997; 107(2):347-52.

11. D’Aiuto F, Nibali L, Parkar M, Suvan J, Tonetti MS. Short-term effects of intensive periodontal therapy on serum inflammatory
markers and cholesterol. J Dent Res. 2005; 84(3):269-73.

12. Paraskevas S, Huizinga JD, Loos BG. A systematic review and meta-analyses on C-reactive protein in relation to periodontitis. J Clin Periodontol. 2008; 35(4):277-90.

13. Sorsa T. Tjäderhane T., Salo T. Matrix metalloproteinases (MMPs) in oral diseases. Oral Diseases. 2004; 10(6): 311-8.

14. Sorsa T, Mantyla P, Tervahartiala T, Pussinen PJ, Gamonal J, Hernandez M. MMP activation in diagnostics of periodontitis and systemic inflammation. J Clin Periodontol. 2011; 38(9): 817-9.

15. Tonetti MS, D’Aiuto F, Nibali L, et al. Treatment of periodontitis and endothelial function. N Engl J Med. 2007; 356(9): 911-20.

16. Amar S, Gokce N, Morgan S, Loukideli M, Van Dyke TE, Vita JA. Periodontal disease is associated with brachial artery endothelial dysfunction and systemic inflammation. Arterioscler Thromb Vasc Biol. 2003; 23(7):1245-9.

17. Blaizot A, Vergnes JN, Nuwwareh S, Amar J, Sixou M. Periodontal diseases and cardiovascular events: meta-analysis
of observational studies. Int Dent J. 2009; 59(4):197-209.

18. Mattila KJ, Nieminen MS, Valtonen VV, et al. Association between dental health and acute myocardial infarction. BMJ. 1989;
298(6676):779-81.

19. Meurman JH, Sanz M, Janket SJ. Oral health, atherosclerosis, and cardiovascular disease. Crit Rev Oral Biol Med. 2004;
15(6):403-13.

20. Lafaurie GI, Mayorga-Fayad I, Torres MF, Castillo DM, Aya MR, Baron A, Hurtado PA. Periodontopathic microorganisms in peripheric blood after scaling and root planing. J Clin Periodontol 2007; 34(10): 873-9.

21. Chou HH, Yumoto H, Davey M, et al. Porphyromonas gingivalis fimbriadependent activation of inflammatory genes in human aortic endothelial cells. Infect Immun. 2005; 73(9):5367-78.

22. Desvarieux M, Demmer RT, Rundek T, et al. Periodontal microbiota and carotid intima-media thickness: the Oral Infections
and Vascular Disease Epidemiology Study (INVEST). Circulation. 2005; 111(5): 576- 82.

23. Spahr A, Klein E, Khuseyinova N, et al. Periodontal infections and coronary heart disease: role of periodontal bacteria and importance of total pathogen burden in the Coronary Event and Periodontal Disease (CORODONT) study. Arch Intern Med.
2006; 166(5):554-9.

24. Nonnenmacher C, Stelzel M, Susin C. Periodontal Microbiota in Patients With Coronary Artery Disease Measured by Real-Time Polymerase Chain Reaction: A Case-Control Study. J Periodontol. 2007; 78 (9): 1724-30.

25. Joshipura KJ, Wand HC, Merchant AT, Rimm EB. Periodontal disease and biomarkers related to cardiovascular disease. J Dent Res 2004; 83(2): 151-5.

26. Elter JR, Hinderliter AL, Offenbacher S, Beck JD, Caughey M, Brodala N, et al. The effects of periodontal therapy on vascular endothelial function: a pilot trial. Am Heart. J 2006; 151(1):47-e1

27. Mustapha IZ, Debrey S, Oladubu M, Ugarte R. Markers of systemic bacterial exposure in periodontal disease and cardiovascular disease risk: a systematic review and meta-analysis. J Periodontol. 2007; 78(12):2289-302

28. Bahekar AA, Singh S,Saha S,Molnar J, Arora R. The prevalence and incidence of coronary heart disease is significantly
increased in periodontitis: A meta-analysis. Am Heart Journal 2007; 154 (5): 830-7.

29. Loos BG. Sys t emi c Ma rke r s of Inflammation in Periodontitis Systemic Markers of Inflammation in Periodontitis. J Periodontol 2005; 76(11-s): 2106-15.

30. I de M, McPartlin D, Coward PY, Crook M. Effect of treatment of chronic periodontitis on levels of serum markers of acute-phase inflammatory and vascular responses. J Clinic periodontol. 2003;
30(4): 334-340

31. D’Aiuto F, Ready D, Tonetti MS. Periodontal disease and C-reactive protein-associated cardiovascular risk. J Periodontal Res. 2004; 39(4): 236-241.

32. Yamazaki K, Ohsawa Y, Itoh H, Ueki K, Tabeta K, Oda T, et al. T-cell clonality to Porphyromonas gingivalis and human heat shock protein 60s in patients with atherosclerosis and periodontitis. Oral Microbiol Immunol. 2004; 19(3):160-7.

33. Behle JH, Sedaghatfar MH, Demmer RT. Heterogeneity of systemic inflammatory responses to periodontal therapy. J Clinic
Periodontol 2009; 36(4): 287-294

34. Armitage, G. C. Development of a classification system for periodontal diseases and conditions. Annals of periodontal 1999; 4(1):1-6.

35. Jaramillo A, Lafaurie GI, Millan LV, et al. Association between periodontal disease and plasma levels of cholesterol and triglycerides. Colomb Med 2013; 44(2): 80-86.

36. Lopez NJ, Quintero A, Casanova PA, Ibieta CI, Baelum V, Lopez R. Effects of periodontal therapy on systemic markers of inflammation in patients with metabolic syndrome: a controlled clinical trial. J Periodontol. 2012; 83(3):267-78

37. Quirynen M, Bollen CML. Full-Vs. Partial-mouth desinfection in the treatment of periodontal infections: short-term clinical and microbiological observations. J Dent Res. 1995; 74(8):1459-67

38. Paraskevas S, Huizinga JD, Loos BG. A systematic review and meta-analyses on C-reactive protein in relation to periodontitis. J Clinic Periodontol. 2008; 35(4):277-290

39. Ianaro A, Ialenti A, Maffia P, Sautebin L, Rombolà L, Carnuccio R, Iuvone T, D’Acquisto F, Di Rosa M. Antiinflammatory activity of macrolide antibiotics. J Pharmacol Exp Ther. 2000; 292(1):156-63.

40. Pussinen PJ, Mattila K. Periodontal infections and atherosclerosis: mere associations? Curr Opin Lipidol. 2004;15(5):583-8.

41. Pejcic A, Kesic L, Brkic Z, Pesic Z, Mirkovic D. Effect of periodontal treatment on lipoproteins levels in plasma in patients with periodontitis. South Med J. 2011; 104(8):547-52

42. Ribeiro CMP, Hurd H, Wu Y, Martino MEB, Jones L, et al. (2009) Azithromycin Treatment Alters Gene Expression in Inflammatory, Lipid Metabolism, and Cell Cycle Pathways in Well-Differentiated Human Airway Epithelia. PLoS ONE 4(6): e5806

43. Elisa Kallio KA, Hyvärinen K, Kovanen PT, Pussinen PJ. Very low density lipoproteins derived from periodontitis patients facilitate macrophage activation via lipopolysaccharide function. Metabol Clinic Exp. 2013; 62(5):661-8.

44. Herrera D, Sanz M, Jepsen S, Needleman I, Roldan S. A systematic review on the effect of systemic antimicrobials as an adjunct to scaling and root planing in periodontitis patients. J Clin Periodontol. 2002; 29(Suppl 3):136-59

45. Guerrero A, Griffiths GS, Nibali L, et al. Adjunctive benefits of systemic amoxicillin and metronidazole in non-surgical treatment of generalized aggressive periodontitis: a randomized placebo-controlled clinical trial. J Clin Periodontol. 2005; 32(10):1096-107

46. Haffajee AD, Torresyap G, Socransky SS. Clinical changes following four different periodontal therapies for the treatment of chronic periodontitis: 1-year results. J Clin Periodontol. 2007; 34(3):243-53.

47. Haas AN, de Castro GD, Moreno T, et al. Azithromycin as an adjunctive treatment of aggressive periodontitis: 12-months randomized clinical trial. J Clin Periodontol. 2008; 35(8):696-704.

48. Yashima A, Gomi K, Maeda N, Arai T. One-stage full-mouth versus partialmouth scaling and root planing during the effective half-life of systemically administered azithromycin. J Periodontol. 2009; 80(9):1406-13.

49. Gomi K, Yashima A, Nagano T, Kanazashi M, Maeda N, Arai T. Effects of full-mouth scaling and root planing in conjunction with systemically administered azithromycin. J Periodontol. 2007; 78(3):422-9.

50. Mascarenhas P, Gapski R, Al-Shammari K, et al. Clinical response of azithromycin as an adjunct to non-surgical periodontal therapy in smokers. J Periodontol. 2005; 76(3):426-36.

51. Smith SR, Foyle DM, Daniels J, et al. A double-blind placebo-controlled trial of azithromycin as an adjunct to non-surgical treatment of periodontitis in adults: clinical results. J Clin Periodontol. 2002; 29(1):54-61.

52. Pradeep AR, Sagar SV, Daisy H. Clinical and microbiologic effects of subgingivally delivered 0.5% azithromycin in the treatment of chronic periodontitis. J Periodontol. 2008; 79(11): 2125-35.

53. Gomi K, Yashima A, Iino F, et al. Drug concentration in inflamed periodontal tissues after systemically administered azithromycin. J Periodontol. 2007; 78(5): 918-23.

54. Herrera D, Alonso B, Leon R, Roldan S, Sanz M. Antimicrobial therapy in periodontitis: the use of systemic antimicrobials against the subgingival biofilm. J Clin Periodontol. 2008; 35(s8): 45-66.

55. Sanz M, Teughels W. Innovations in nonsurgical periodontal therapy: Consensus Report of the Sixth European Workshop on Periodontology. J Clin Periodontol. 2008; 35(s8):3-7

56. Contopoulos-Ioannidis DG, Ioannidis JP, Chew P, Lau J. Meta-analysis of randomized controlled trials on the comparative efficacy and safety of azithromycin against other antibiotics for lower respiratory tract infections. J Antimicrob Chemother. 2001; 48(5):691-703.

57. Casey JR, Pichichero ME. Higher dosages of azithromycin are more effective in treatment of group A streptococcal tonsillopharyngitis. Clin Infect Dis. 2005; 40(12):1748-55.

58. Dastoor SF, Travan S, Neiva RF, Rayburn LA, Giannobile WV, Wang HL. Effect of adjunctive systemic azithromycin with periodontal surgery in the treatment of chronic periodontitis in smokers: A pilot study. J Periodontol. 2007; 78(10):1887-96

59. Veloo AC, Seme K, Raangs E, et al. Antibiotic susceptibility profiles of oral pathogens. Int J Antimicrob Agents. 2012; 40(5): 450-4.

60. van Winkelhoff AJ, Herrera D, Oteo A, Sanz M. Antimicrobial profiles of periodontal pathogens isolated from periodontitis patients in The Netherlands and Spain. J Clin Periodontol. 2005; 32(8): 893-8.

61. Sefton AM, Maskell JP, Beighton D, et al. Azithromycin in the treatment of periodontal disease. Effect on microbial flora. J Clin Periodontol. 1996; 23(11): 998-1003.

62. Jaramillo Echeverri A, Betancourth Quiroz M, Mayorga-Fayad I, et al. Perfiles Antimicrobianos de Bacterias Subgingival es en Pa ci ent e s con Periodontitis en Colombia. Revista Clínica de Periodoncia, Implantología y Rehabilitación Oral. 2008; 1(2):61-5.
Published
2017-09-30
How to Cite
SOTO-FRANCO, Jorge-Enrique et al. High sensitive- C reactive protein, periodontal parameters and periodontal microbiota after scaling-root planning plus Azithromycin as treatment of Chronic Periodontitis: A Randomized Clinical Trial. Revista Estomatología, [S.l.], v. 24, n. 2, sep. 2017. ISSN 2248-7220. Available at: <http://revistas.univalle.edu.co/index.php/revista_estomatologia/article/view/5798>. Date accessed: 11 dec. 2018. doi: https://doi.org/10.25100/re.v24i2.5798.
Section
Original Articles

Keywords

Chronic periodontitis, azitromycin, randomized clinical trial, C reactive protein